Olle Sangfelt

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: MOLECULAR CELL. 2023;83(20):3720-3739.e8

FBXL12 degrades FANCD2 to regulate replication recovery and promote cancer cell survival under conditions of replication stress.

Brunner A; Li Q; Fisicaro S; Kourtesakis A; Viiliäinen J; Johansson HJ; Pandey V; Mayank AK; Lehtiö J; Wohlschlegel JA; Spruck C; Rantala JK; Orre LM; Sangfelt O
Article: CANCER RESEARCH. 2022;82(24):4586-4603

Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma.

Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundström A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schüller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Article: MOLECULAR CELL. 2022;82(6):1123-1139.e8

A FBXO7/EYA2-SCFFBXW7 axis promotes AXL-mediated maintenance of mesenchymal and immune evasion phenotypes of cancer cells.

Shen JZ; Qiu Z; Wu Q; Zhang G; Harris R; Sun D; Rantala J; Barshop WD; Zhao L; Lv D; Won K-A; Wohlschlegel J; Sangfelt O; Laman H; Rich JN; Spruck C
Article: SCIENTIFIC REPORTS. 2021;11(1):11023

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Suryo Rahmanto A; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Frostvik Stolt M; Tuominen R; Sangfelt O; Pokrovskaja Tamm K; Hansson J; Grandér D; Egyházi Brage S; Johnsson P
Article: ONCOTARGET. 2021;12(11):1100-1109

Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.

Mäkelä R; Härmä V; Badra Fajardo N; Wells G; Lygerou Z; Sangfelt O; Kononen J; Rantala JK
Article: ONCOGENE. 2021;40(13):2367-2381

A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma.

Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
Article: CELL. 2021;184(2):352-369.e23

FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells.

Shen JZ; Qiu Z; Wu Q; Finlay D; Garcia G; Sun D; Rantala J; Barshop W; Hope JL; Gimple RC; Sangfelt O; Bradley LM; Wohlschlegel J; Rich JN; Spruck C
Article: SCIENTIFIC REPORTS. 2020;10(1):22334

K63-linked ubiquitylation induces global sequestration of mitochondria.

Richard TJC; Herzog LK; Vornberger J; Rahmanto AS; Sangfelt O; Salomons FA; Dantuma NP
Article: GENOME MEDICINE. 2020;12(1):99

Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities.

Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Mäkinen A; Laukkanen S; Mäkinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lönnberg T; Lohi O; Heinäniemi M
Article: NEOPLASIA. 2020;22(9):390-398

Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma.

Mäkelä R; Arjonen A; Suryo Rahmanto A; Härmä V; Lehtiö J; Kuopio T; Helleday T; Sangfelt O; Kononen J; Rantala JK
Article: ELIFE. 2020;9:e57894

PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer.

Brunner A; Suryo Rahmanto A; Johansson H; Franco M; Viiliäinen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtiö J; Rantala JK; Larsson L-G; Sangfelt O
Article: MOLECULAR AND CELLULAR ONCOLOGY. 2017;4(1):e1252871

Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence.

Suryo Rahmanto A; Swartling FJ; Sangfelt O
Article: EMBO JOURNAL. 2016;35(20):2192-2212

FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma.

Suryo Rahmanto A; Savov V; Brunner A; Bolin S; Weishaupt H; Malyukova A; Rosén G; Čančer M; Hutter S; Sundström A; Kawauchi D; Jones DT; Spruck C; Taylor MD; Cho Y-J; Pfister SM; Kool M; Korshunov A; Swartling FJ; Sangfelt O
Article: FASEB JOURNAL. 2016;30(8):2860-2873

In β-actin knockouts, epigenetic reprogramming and rDNA transcription inactivation lead to growth and proliferation defects.

Almuzzaini B; Sarshad AA; Rahmanto AS; Hansson ML; Von Euler A; Sangfelt O; Visa N; Farrants A-KÖ; Percipalle P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2013;162(2):210-220

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Gatt ME; Takada K; Mani M; Lerner M; Pick M; Hideshima T; Carrasco DE; Protopopov A; Ivanova E; Sangfelt O; Grandér D; Barlogie B; Shaughnessy JD; Anderson KC; Carrasco DR
Article: EMBO MOLECULAR MEDICINE. 2013;5(7):1067-1086

CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer.

Cepeda D; Ng H-F; Sharifi HR; Mahmoudi S; Cerrato VS; Fredlund E; Magnusson K; Nilsson H; Malyukova A; Rantala J; Klevebring D; Viñals F; Bhaskaran N; Zakaria SM; Rahmanto AS; Grotegut S; Nielsen ML; Szigyarto CA-K; Sun D; Lerner M; Navani S; Widschwendter M; Uhlén M; Jirström K; Pontén F; Wohlschlegel J; Grandér D; Spruck C; Larsson L-G; Sangfelt O
Article: LEUKEMIA. 2013;27(5):1053-1062

FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation.

Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM
Article: MOLECULAR AND CELLULAR BIOLOGY. 2013;33(1):85-97

Fbw7α and Fbw7γ collaborate to shuttle cyclin E1 into the nucleolus for multiubiquitylation.

Bhaskaran N; van Drogen F; Ng H-F; Kumar R; Ekholm-Reed S; Peter M; Sangfelt O; Reed SI
Article: NATURE COMMUNICATIONS. 2012;3:976

Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway.

Arabi A; Ullah K; Branca RMM; Johansson J; Bandarra D; Haneklaus M; Fu J; Ariës I; Nilsson P; Den Boer ML; Pokrovskaja K; Grandér D; Xiao G; Rocha S; Lehtiö J; Sangfelt O
Article: CELL CYCLE. 2011;10(13):2172-2183

MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression.

Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng H-F; Akbari Moqadam F; Oude Vrielink JAF; Agami R; Den Boer ML; Grandér D; Sangfelt O
Article: BREAST CANCER RESEARCH. 2010;12(6):R105

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Akhoondi S; Lindström L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grandér D; Sangfelt O
Article: SCIENCE. 2009;326(5953):718-721

Control of iron homeostasis by an iron-regulated ubiquitin ligase.

Vashisht AA; Zumbrennen KB; Huang X; Powers DN; Durazo A; Sun D; Bhaskaran N; Persson A; Uhlen M; Sangfelt O; Spruck C; Leibold EA; Wohlschlegel JA
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(17):2941-2952

DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1.

Lerner M; Harada M; Lovén J; Castro J; Davis Z; Oscier D; Henriksson M; Sangfelt O; Grandér D; Corcoran MM
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(11):1832-1839

SCF(Fbxw7/hCdc4) targets cyclin E2 for ubiquitin-dependent proteolysis.

Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
Article: CANCER CELL. 2009;15(5):441-453

Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis.

Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Article: CELL CYCLE. 2008;7(8):1075-1082

Both SCF(Cdc4alpha) and SCF(Cdc4gamma) are required for cyclin E turnover in cell lines that do not overexpress cyclin E.

Sangfelt O; Cepeda D; Malyukova A; van Drogen F; Reed SI
Article: CANCER RESEARCH. 2007;67(19):9006-9012

FBXW7/hCDC4 is a general tumor suppressor in human cancer.

Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: EXPERIMENTAL CELL RESEARCH. 2007;313(14):3141-3152

Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines.

Dohda T; Maljukova A; Liu L; Heyman M; Grandér D; Brodin D; Sangfelt O; Lendahl U
Article: CANCER RESEARCH. 2007;67(12):5611-5616

The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling.

Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grandér D; Lendahl U; Sangfelt O
Article: MOLECULAR BIOLOGY OF THE CELL. 2007;18(5):1670-1682

The RBCC gene RFP2 (Leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD.

Lerner M; Corcoran M; Cepeda D; Nielsen ML; Zubarev R; Pontén F; Uhlén M; Hober S; Grandér D; Sangfelt O
Article: MOLECULAR CELL. 2006;23(1):37-48

Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms.

van Drogen F; Sangfelt O; Malyukova A; Matskova L; Yeh E; Means AR; Reed SI
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 2005;25(2):63-72

The HPV-16 E7 oncogene sensitizes malignant cells to IFN-alpha-induced apoptosis.

Thyrell L; Sangfelt O; Zhivotovsky B; Pokrovskaja K; Wang Y; Einhorn S; Grandér D
Article: HUMAN MOLECULAR GENETICS. 2004;13(23):2925-2936

Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia.

Hammarsund M; Lerner M; Zhu C; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grandér D; Sangfelt O; Corcoran M
Article: GENES CHROMOSOMES & CANCER. 2004;40(4):285-297

DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse.

Corcoran MM; Hammarsund M; Zhu C; Lerner M; Kapanadze B; Wilson B; Larsson C; Forsberg L; Ibbotson RE; Einhorn S; Oscier DG; Grandér D; Sangfelt O
Article: CANCER RESEARCH. 2004;64(3):795-800

Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer.

Ekholm-Reed S; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
Article: FEBS LETTERS. 2004;556(1-3):75-80

Characterization of a novel B-CLL candidate gene--DLEU7--located in the 13q14 tumor suppressor locus.

Hammarsund M; Corcoran MM; Wilson W; Zhu C; Einhorn S; Sangfelt O; Grandér D
Article: GENE. 2003;321:103-112

Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OS.

Baranova A; Hammarsund M; Ivanov D; Skoblov M; Sangfelt O; Corcoran M; Borodina T; Makeeva N; Pestova A; Tyazhelova T; Nazarenko S; Gorreta F; Alsheddi T; Schlauch K; Nikitin E; Kapanadze B; Shagin D; Poltaraus A; Ivanovich Vorobiev A; Zabarovsky E; Lukianov S; Chandhoke V; Ibbotson R; Oscier D; Einhorn S; Grander D; Yankovsky N
Article: CANCER RESEARCH. 2002;62(16):4535-4539

hCDC4 gene mutations in endometrial cancer.

Spruck CH; Strohmaier H; Sangfelt O; Müller HM; Hubalek M; Müller-Holzner E; Marth C; Widschwendter M; Reed SI
Article: ONCOGENE. 2002;21(8):1251-1262

Mechanisms of Interferon-alpha induced apoptosis in malignant cells.

Thyrell L; Erickson S; Zhivotovsky B; Pokrovskaja K; Sangfelt O; Castro J; Einhorn S; Grandér D
Article: FEBS JOURNAL. 2002;269(1):29-37

Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes.

Erickson S; Matikainen S; Thyrell L; Sangfelt O; Julkunen I; Einhorn S; Grandér D
Article: RUSSIAN JOURNAL OF GENETICS. 2001;37(11):1286-1292

The transcription map of the 13q14 region frequently deleted in B-cell chronic lymphocytic leukemia

Tyazhelova TV; Ivanov DV; Makeeva NV; Kapanadze BI; Nikitin EA; Semov AB; Sangfelt O; Grander D; Vorobiev AI; Einhorn S; Yankovsky NK; Baranova AV
Article: HUMAN GENETICS. 2001;109(5):542-550

Identification and characterization of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution.

Hammarsund M; Wilson W; Corcoran M; Merup M; Einhorn S; Grandér D; Sangfelt O
Article: NATURE. 2001;413(6853):316-322

Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line.

Strohmaier H; Spruck CH; Kaiser P; Won KA; Sangfelt O; Reed SI
Article: GENOMICS. 2000;70(3):327-334

Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14.

Kapanadze B; Makeeva N; Corcoran M; Jareborg N; Hammarsund M; Baranova A; Zabarovsky E; Vorontsova O; Merup M; Gahrton G; Jansson M; Yankovsky N; Einhorn S; Oscier D; Grandér D; Sangfelt O
Article: BLOOD. 2000;96(13):4313-4318

Interferon alpha down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells.

Xu D; Erickson S; Szeps M; Gruber A; Sangfelt O; Einhorn S; Pisa P; Grandér D
Article: MOLECULAR CANCER RESEARCH. 1999;10(8):575-582

Interferon-alpha inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins.

Erickson S; Sangfelt O; Castro J; Heyman M; Einhorn S; Grandér D
Article: ONCOGENE. 1999;18(18):2798-2810

Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.

Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 1998;18(9):691-695

In vivo induction of the interferon-stimulated protein 2'5'-oligoadenylate synthetase in tumor and peripheral blood cells during IFN-alpha treatment of metastatic melanoma.

Grandér D; Sangfelt O; Skoog L; Hansson J
Article: ONCOGENE. 1998;17(5):595-602

Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence.

Erickson S; Sangfelt O; Heyman M; Castro J; Einhorn S; Grandér D
Article: MOLECULAR CANCER RESEARCH. 1997;8(3):343-352

Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines.

Sangfelt O; Erickson S; Castro J; Heiden T; Einhorn S; Grandér D
Article: ONCOGENE. 1997;14(4):415-423

Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines.

Sangfelt O; Erickson S; Einhorn S; Grandér D
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(1):106-112

Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma.

Sangfelt O; Einhorn S; Björklund AC; Wiman KG; Okan I; Grandér D
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1996;31(6):604-611

Factors influencing the response to interferon therapy in chronic hepatitis C. Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells.

Grandér D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Björklund AC; Befrits R; Björkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192

Response to interferon therapy in patients with multiple myeloma correlates with expression of the Bcl-2 oncoprotein.

Sangfelt O; Osterborg A; Grandér D; Anderbring E; Ost A; Mellstedt H; Einhorn S
Visa fler

Alla övriga publikationer

Corrigendum: CANCER CELL. 2017;31(5):724-726

Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis.

Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Review: ONCOGENE. 2014;33(39):4709-4721

Oncoprotein stabilization in brain tumors.

Hede S-M; Savov V; Weishaupt H; Sangfelt O; Swartling FJ
Review: CANCER LETTERS. 2008;271(1):1-12

The Fbxw7/hCdc4 tumor suppressor in human cancer.

Tan Y; Sangfelt O; Spruck C
Corrigendum: CANCER RESEARCH. 2008;68(6):2051

The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling (vol 67, pg 5611, 2007)

Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grander D; Lendahl U; Sangfelt O
Corrigendum: CANCER RESEARCH. 2008;68(4):1245

The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)

Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Meeting abstract: BLOOD. 2004;104(11):431A

DLEU2, located within the CLL 13q14 deletion locus, encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse

Corcoran MM; Hammarsund M; Zhu CY; Lerner M; Kapanadze B; Larsson C; Forsberg L; Ibbotson RE; Einhorn S; Oscier DG; Grander D; Sangfelt O
Meeting abstract: BLOOD. 2004;104(11):430A

Disruption of the HEXB/ENC-1 antisense gene and identification of elevated ENC-1 expression in patients with Hairy Cell Leukemia

Lerner M; Hammarsund M; Sangfelt O; Zhu CY; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grander D; Corcoran M
Review: MEDICAL ONCOLOGY. 2001;18(1):3-14

Apoptosis and cell growth inhibition as antitumor effector functions of interferons.

Sangfelt; Strander H
Review: FRONTIERS IN BIOSCIENCE - LANDMARK. 2000;5:D479-D487

Mechanisms of interferon-induced cell cycle arrest.

Sangfelt O; Erickson S; Grander D
Review: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;59(3):129-135

How does interferon exert its cell growth inhibitory effect?

Grandér D; Sangfelt O; Erickson S

Anställningar

Senior Forskare, Cell- och molekylärbiologi, Karolinska Institutet, 2022-

Examina och utbildning

Docent, Cellbiologi, Karolinska Institutet, 2011
MEDICINE DOKTORSEXAMEN, Institutionen för onkologi-patologi, Karolinska Institutet, 1998

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI